WallStreetZenWallStreetZen

NASDAQ: CBLL
Ceribell Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for CBLL

Based on 2 analysts offering 12 month price targets for Ceribell Inc

Min Forecast
$26.00+6.69%
Avg Forecast
$28.00+14.9%
Max Forecast
$30.00+23.1%

Should I buy or sell CBLL stock?

Based on 2 analysts offering ratings for Ceribell Inc.

Strong Buy
Strong Buy
2 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although CBLL's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates CBLL as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +5.11% per year. Learn More

Be the first to know when Wall Street analysts revise their CBLL stock forecasts and price targets.

CBLL stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-09-11
lockedlocked$00.00+00.00%2026-08-11Find Out Why

1 of 1

Forecast return on equity

Is CBLL forecast to generate an efficient return?

Company
N/A
Industry
22.47%
Market
168.71%

Forecast return on assets

Is CBLL forecast to generate an efficient return on assets?

Company
N/A
Industry
13.73%

CBLL earnings per share forecast

What is CBLL's earnings per share in the next 3 years based on estimates from 10 analysts?

Avg 1 year Forecast
-$1.93
Avg 2 year Forecast
-$1.47
Avg 3 year Forecast
-$1.30

CBLL revenue forecast

What is CBLL's revenue in the next 3 years based on estimates from 10 analysts?

Avg 1 year Forecast
$117.9M+15.58%
Avg 2 year Forecast
$150.0M+47.15%
Avg 3 year Forecast
$191.5M+87.79%
CBLL's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

CBLL revenue growth forecast

How is CBLL forecast to perform vs Medical Devices companies and vs the US market?

Company
22.93%
Industry
7.26%
Market
13.78%
CBLL's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
CBLL's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

CBLL vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
CBLL$24.37$28.00+14.90%Strong Buy
BBNX$21.89$21.00-4.07%Buy
INMD$14.35$16.50+14.98%Buy
ENOV$18.04$38.63+114.11%Strong Buy
IRMD$82.12$116.00+41.26%Strong Buy
View Top Medical Device Stocks

Ceribell Stock Forecast FAQ

Is Ceribell Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: CBLL) stock is to Strong Buy CBLL stock.

Out of 2 analysts, 2 (100%) are recommending CBLL as a Strong Buy, 0 (0%) are recommending CBLL as a Buy, 0 (0%) are recommending CBLL as a Hold, 0 (0%) are recommending CBLL as a Sell, and 0 (0%) are recommending CBLL as a Strong Sell.

If you're new to stock investing, here's how to buy Ceribell stock.

What is CBLL's earnings growth forecast for 2026-2028?

(NASDAQ: CBLL) Ceribell's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Devices industry's average forecast earnings growth rate of 22.02%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.22%.

Ceribell's earnings in 2026 is -$65,997,000.On average, 10 Wall Street analysts forecast CBLL's earnings for 2026 to be -$74,035,195, with the lowest CBLL earnings forecast at -$77,477,710, and the highest CBLL earnings forecast at -$68,101,940. On average, 10 Wall Street analysts forecast CBLL's earnings for 2027 to be -$56,565,483, with the lowest CBLL earnings forecast at -$67,698,970, and the highest CBLL earnings forecast at -$41,908,886.

In 2028, CBLL is forecast to generate -$50,010,503 in earnings, with the lowest earnings forecast at -$65,442,338 and the highest earnings forecast at -$31,431,665.

What is CBLL's revenue growth forecast for 2026-2028?

(NASDAQ: CBLL) Ceribell's forecast annual revenue growth rate of 22.93% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.26%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.78%.

Ceribell's revenue in 2026 is $101,964,000.On average, 10 Wall Street analysts forecast CBLL's revenue for 2026 to be $4,522,859,203, with the lowest CBLL revenue forecast at $4,325,211,983, and the highest CBLL revenue forecast at $4,674,452,702. On average, 10 Wall Street analysts forecast CBLL's revenue for 2027 to be $5,758,250,274, with the lowest CBLL revenue forecast at $5,453,528,152, and the highest CBLL revenue forecast at $6,049,923,842.

In 2028, CBLL is forecast to generate $7,348,638,779 in revenue, with the lowest revenue forecast at $6,845,118,094 and the highest revenue forecast at $7,850,240,560.

What is CBLL's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: CBLL) forecast ROA is N/A, which is lower than the forecast US Medical Devices industry average of 13.73%.

What is CBLL's Price Target?

According to 2 Wall Street analysts that have issued a 1 year CBLL price target, the average CBLL price target is $28.00, with the highest CBLL stock price forecast at $30.00 and the lowest CBLL stock price forecast at $26.00.

On average, Wall Street analysts predict that Ceribell's share price could reach $28.00 by Sep 11, 2027. The average Ceribell stock price prediction forecasts a potential upside of 14.9% from the current CBLL share price of $24.37.

What is CBLL's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: CBLL) Ceribell's current Earnings Per Share (EPS) is -$1.76. On average, analysts forecast that CBLL's EPS will be -$1.93 for 2026, with the lowest EPS forecast at -$2.02, and the highest EPS forecast at -$1.77. On average, analysts forecast that CBLL's EPS will be -$1.47 for 2027, with the lowest EPS forecast at -$1.76, and the highest EPS forecast at -$1.09. In 2028, CBLL's EPS is forecast to hit -$1.30 (min: -$1.71, max: -$0.82).

What is CBLL's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: CBLL) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.